Quiero saber acerca de...

11546

Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices
Divided into two comprehensive activity categories: State-level Activities and State Leadership Activities, according to Section 4 of the AT Act, as a condition of receiving a grant to support their Statewide AT
Programs, the 56 states and outlying areas must provide to ACL: 1
Applications and 2 annual progress reports on their activities.
Applications: The application required of states and outlying areas is a three-year State Plan for Assistive Technology State Plan for AT or State Plan OMB No. 09850048. The content of the State Plan for AT is based on the requirements in Section 4d of the AT Act.
Annual Reports: In addition to submitting a State Plan, every three years, states and outlying areas are required to submit annual progress reports on their activities. The data required in that progress report is specified in Section 4f of the AT Act OMB No. 09850042.
National aggregation of data related to measurable goals is necessary for the Government Performance and Results Modernization Act of 2010 GPRAMA
Pub. L. 111352, as well as an Annual Report to Congress see Section 7

Requirements Necessitating Collection below. Therefore, this data collection instrument provides a way for all 56
grantees50 U.S. states, DC, Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, and the Commonwealth of the Northern Mariana Islands to collect and report data on their activities in a consistent manner, including a uniform survey to be given to consumers. This uniform survey is included as part of the data collection package.
Section 7d of the AT Act requires that ACL submit to Congress an annual report on the activities conducted under the Act and an analysis of the progress of the states and outlying areas in meeting their measurable goals. This report must include a compilation and summary of the data collected under Section 4f. In order to make this possible, states and outlying areas must provide their data uniformly. This data collection instrument was developed to ensure that all 56 states and outlying areas report data in a consistent manner in alignment with the requirements of Section 4f.
As stated above, ACL will use the information collected via this instrument to:

1 Complete the annual report to Congress required by the AT Act;
2 Comply with reporting requirements under the Government Performance and Results Modernization Act of 2010 GPRAMA Pub. L. 111
352; and 3 Assess the progress of states and outlying areas regarding measurable goals. Data collected from the grantees will provide a national description of activities funded under the AT Act to increase the access to and acquisition of AT devices and services through statewide AT programs for individuals with disabilities. Data collected from grantees will also provide information for usage by Congress, the Department, and the public. In addition, ACL will use this data to inform program management, monitoring, and technical assistance efforts. States will be able to use the data for internal management and program improvement.
To review the proposed data collection tools please visit the ACL
website at: https www.acl.gov/aboutacl/public-input.
Estimated Program Burden: ACL
estimates the burden associated with this collection of information as follows:

Respondent/data collection activity
Number of respondents
Responses per respondent
Hours per response
Annual burden hours
State Plan for Assistive Technology

56

1

73.0

4,088

Dated: February 19, 2021.
Alison Barkoff, Acting Administrator and Assistant Secretary for Aging.
FR Doc. 202103868 Filed 22421; 8:45 am BILLING CODE 415401P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health Government-Owned Inventions;
Availability for Licensing AGENCY:

National Institutes of Health,
HHS.
ACTION:

Notice.

The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage
SUMMARY:

VerDate Sep<11>2014

17:04 Feb 24, 2021

Jkt 253001

for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Soukas, J.D., 3015948730;
peter.soukas@nih.gov. Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
3014962644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus RSV
Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P
Gene Description of Technology:
RSV is the most important viral agent of severe respiratory disease in infants
PO 00000

Frm 00052

Fmt 4703

Sfmt 4703

and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with many deaths occurring in developing countries. However, despite the prevalence of RSV and the dangers associated with infection, no RSV vaccine has been successfully developed to date. Accordingly, there is a public health need for RSV vaccines.
This vaccine candidate comprises live RSV that was attenuated by subjecting the protein-coding sequences of the viral NS1, NS2, N, P, M, and SH genes to codon-pair deoptimization, which resulted in many nucleotide substitutions that were silent at the amino acid level but conferred attenuation. In addition, specific amino acid substitutions were identified and introduced into the P protein that improved attenuation and genetic stability. Genetic stability was confirmed in vitro, and attenuation was confirmed in experimental animals.

E:FRFM25FEN1.SGM

25FEN1